Hollis-Eden Pharmaceuticals Presents Positive Updated Data from Phase I/II Clinical Trial with TRIOLEX(TM) in Obese Insulin Resi
25 Septiembre 2008 - 6:00AM
Business Wire
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today presented
additional positive interim data from its on-going Phase I/II
clinical trial with its investigational oral drug candidate
TRIOLEX� (HE3286) in obese insulin resistant subjects at the 6th
World Congress on Insulin Resistance Syndrome, being held September
25th � 27th in Los Angeles, California. Dr. Jaime Flores-Riveros,
Vice President, Endocrinology and Metabolism at Hollis-Eden
Pharmaceuticals, presented the data. The additional data extend
findings previously reported in a corporate symposium held in
conjunction with the 68th Scientific Sessions of the American
Diabetes Association demonstrating that TRIOLEX is safe and well
tolerated to date, and that it significantly improved insulin
sensitivity and lowered fasting blood glucose and insulin levels in
obese insulin resistant subjects treated orally with 5 or 10
milligrams of the compound administered twice daily for 28 days, as
compared to placebo-treated subjects. Dr. Flores-Riveros presented
additional data showing that insulin resistant subjects (as defined
by a physiological index of glucose disposal or M-value less than
5), displayed a significantly exacerbated inflammatory response
characterized by higher levels of the pro-inflammatory cytokines
MCP-1, TNF-alpha, IL-6 and IL-1beta produced in LPS stimulated
peripheral blood mononuclear cells (PBMC) from these patients. In
contrast to more insulin sensitive subjects (M>5), treatment of
these insulin resistant subjects (M
Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Hollis-Eden Pharmaceuticals (MM) (NASDAQ:HEPH)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Hollis-Eden Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de Hollis-Eden Pharmaceuticals, Inc. Artículos de Noticias